TNM classifications have been established for various
|
|
- Ross Lyons
- 5 years ago
- Views:
Transcription
1 Lymphogenous and Hematogenous Metastasis of Thymic Epithelial Tumors Kazuya Kondo, MD, PhD, and Yasumasa Monden, MD, PhD Department of Oncological and Regenerative Surgery, School of Medicine, University of Tokushima, Tokushima, Japan GENERAL THORACIC Background. A TNM classification has been established for various tumors. However, the TNM classification of thymic epithelial tumor has not been established yet. Methods. We received replies to a questionnaire on thymic epithelial tumors from 115 institutes. We compiled a database of 1,320 patients with thymic epithelial tumor (1,093 thymomas, 186 thymic carcinomas, and 41 thymic carcinoids) who were treated between 1990 and We used a tentative TNM classification of thymoma presented by Yamakawa and associates in The regional lymph nodes of the thymus were classified into three groups: anterior mediastinal lymph nodes (N1), intrathoracic lymph nodes (N2), and extrathoracic lymph nodes (N3). Results. The rate of lymphogenous metastasis in thymoma, thymic carcinoma, and thymic carcinoid was 1.8%, 27%, and 28%, respectively. Most tumors with lymph node metastasis metastasized to N1 (thymoma, 90%; thymic carcinoma, 69%; thymic carcinoid, 91%). The 5-year survival rates of N0, N1, and N2 thymoma were 96%, 62%, and 20%, respectively. The 5-year survival rates of N0, N1, N2, and N3 thymic carcinoma were 56%, 42%, 29%, and 19%, respectively. The 5-year survival rates of M0 and M1 thymoma were 95% and 57%. The 5-year survival rates of M0 and M1 thymic carcinoma were 51% and 35%. Multivariate analysis demonstrated that survival of patients with thymoma was dependent on the clinical stage of Masaoka and complete resection. In thymic carcinoma, survival was dependent on lymph node metastasis and complete resection. Conclusions. The N factor was one of the predictors of survival in thymoma and thymic carcinoma. However, M factor showed less influence on survival than T or N factors. (Ann Thorac Surg 2003;76: ) 2003 by The Society of Thoracic Surgeons TNM classifications have been established for various tumors, and we can predict the prognosis of a patient with a malignant tumor and choose the therapy by the clinical stage on the basis of the classification. However, the TNM classification of thymic epithelial tumor has not been established yet. We think that the main reason for this is that the influence of the N or M factor on prognosis in thymic epithelial tumors is not clear. The clinical staging of thymoma, which is one of the thymic epithelial tumors, has been revised and updated during the years [1 3]. The idea of clinical staging of thymoma was introduced by Bergh and colleagues [1] and later modified by Wilkins and Castleman [2], and was almost established by Masaoka and associates in 1981 [3]. The staging system of Masaoka and associates is the most popular system for thymoma now. In this system, the state of local invasion by thymoma (T factor) is strongly emphasized in comparing lymphogenous and hematogenous metastasis (N and M factors) because of the rarity of lymphogenous or hematogenous metastasis in thymoma. Although the T factor is classified into four categories (stages I, II, III, and IVA) according to the Accepted for publication June 3, Address reprint requests to Dr Kondo, Department of Oncological and Regenerative Surgery, School of Medicine, University of Tokushima, Kuramoto-cho, Tokushima , Japan; kondo@clin.med. tokushima-u.ac.jp. degree of local invasion, both lymphogenous and hematogenous metastasis are classified as stage IVB. Suster and Moran [4] emphasized that a system for pathologic and clinical staging should be adapted to the entire spectrum of thymic epithelial tumors. Thymic carcinoma or carcinoid frequently metastasizes lymphogenously or hematogenously [5 7]. It is necessary to analyze the pattern of lymphogenous or hematogenous metastasis and determine whether or not these metastases influence the prognosis in thymic carcinoma and carcinoid. However, because of the rarity of the thymic carcinoma and carcinoid, most published series involve only small numbers of patients. In our previous study, we compiled a database of 1,093 thymomas, 186 thymic carcinomas, and 41 thymic carcinoids treated between 1990 and 1994 at 115 institutes in Japan [8]. We demonstrated that the clinical stage of Masaoka and coworkers [3] is an excellent system for predicting prognoses not only in thymoma but also in thymic carcinoma, and that radical surgery is the most important factor in survival rate from thymic epithelial tumor [8]. However, it is unknown whether the addition of radiation or chemotherapy to the surgery can prolong survival and prevent the recurrence in invasive thymoma and thymic carcinoma [8]. In the present study, we analyzed the pattern of lymphogenous or hematogenous metastasis of thymic epithelial tumor, and determined whether N or M factor can be predictors of survival. We would hope to contribute to the estab by The Society of Thoracic Surgeons /03/$30.00 Published by Elsevier Inc doi: /s (03)
2 GENERAL THORACIC 1860 KONDO AND MONDEN Ann Thorac Surg METASTASIS OF THYMIC EPITHELIAL TUMORS 2003;76: Table 1. TNM Classification of Thymic Epithelial Tumors T factor T1: Macroscopically completely encapsulated and microscopically no capsular invasion T2: Macroscopically adhesion or invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into capsule T3: Invasion into neighboring organs, such as pericardium, great vessels, and lung T4: Pleural or pericardial dissemination N factor N0: No lymph node metastasis N1: Metastasis to anterior mediastinal lymph nodes N2: Metastasis to intrathoracic lymph nodes except anterior mediastinal lymph nodes N3: Metastasis to extrathoracic lymph nodes M factor M0: No hematogenous metastasis M1: Hematogenous metastasis lishment of a TNM classification for thymic epithelial tumor. Material and Methods Patients We sent a questionnaire on thymic epithelial tumors to 185 institutes certified by the Japanese Association for Chest Surgery, and received replies from 115 institutes (62%). We compiled a database of 1,320 patients with thymic epithelial tumor who were treated between 1990 and These patients included 1,093 thymomas (82.8%), 186 thymic carcinomas (14.1%), and 41 thymic carcinoids (3.1%). Final pathologic staging was decided by a tentative TNM classification of thymoma (Table 1) presented by Yamakawa and associates in 1991 [9]. The pleural spread of thymoma was considered T4. The regional lymph nodes of the thymus were classified into three groups: anterior mediastinal lymph nodes (N1), intrathoracic lymph nodes except anterior mediastinal lymph nodes (N2), and extrathoracic lymph nodes (N3). When the lymph node metastasis to N1, N2, or N3 was positive, we denoted N1, N2, or N3, respectively. When the lymph node metastasis to N1, N2, or N3 was negative, we denoted N1,N2,orN3, respectively. When any of N1, N2, or N3 was positive, we denoted N. And when all of N1, N2 and N3 were negative, we denoted N. We decided that the postoperative pathologic findings judged the lymph node metastasis for operable cases, and that computed tomography or magnetic resonance imaging judged it for inoperable cases. Statistical Analysis Survival analysis was performed by the method of Kaplan-Meier, and comparisons of survival by the logrank test were made. Multivariate analysis by the Cox proportional hazards model using SPSS for Windows (version ; SPSS Inc, Chicago, IL) was performed. Possible factors for inclusion in the model consisted of sex, age, histologic type (spindle cell type versus not spindle cell type in thymoma, squamous cell carcinoma versus not squamous cell carcinoma in thymic carcinoma), complications (myasthenia gravis, pure red cell aplasia, and hypergammaglobulinemia or hypogammaglobulinemia), clinical stage by Masaoka and coworkers [3] (I and II versus III and IV), lymph node metastasis, distant metastasis, and type of surgery (complete resection versus subtotal resection and inoperable). All clinical data refer to our previous reports [8]. Significance was defined as a p value less than Deaths as a result of complications (eg, myasthenia gravis and pure red cell aplasia) or unrelated disease were excluded. Results Lymph Node Metastasis of Thymic Epithelial Tumors Figure 1 demonstrates the lymph node metastasis of thymoma, thymic carcinoma, and thymic carcinoid. Only 19 cases (1.8%) of 1,064 thymomas metastasized to lymph nodes. N thymoma consisted of 14 (N1 and N2 ) thymomas, 3 (N1 and N2 ) ones, and 2 (N1 and N2 ) ones. None of the thymomas was N3 (Fig 1A). Forty-nine cases (26.8%) of 183 thymic carcinomas metastasized to lymph nodes. N carcinoma consisted of 34 N1 (69.4%), 17 N2 (34.7%), and 15 N3 (30.6%) carcinomas. Nineteen cases (55.9%) of N1 carcinoma metastasized to N1 alone (N1 and N2 and N3 ). Thirteen cases (38.2%) of N1 carcinoma metastasized to either N2 or N3 (N1 and N2 and N3, 10 cases [29.4%]; N1 and N2 and N3, 3 cases [8.8%]). Two cases (5.9%) of N1 carcinoma metastasized to N2 and N3 (N1 and N2 and N3 ). Five cases (29.4%) of N2 carcinoma metastasized to N2 alone (N1 and N2 and N3 ). Ten cases (66.7%) of N3 carcinoma metastasized to N3 alone (N1 and N2 and N3 ). There was no case with (N1 and N2 and N3 ) carcinoma (Fig 1B). Eleven (27.5%) of 40 thymic carcinoids were N.N carcinoids consisted of 10 N1 (90.9%), 5 N2 (45.5%), and3n3 (27.3%) carcinoids. Three cases (30%) of N1 carcinoids metastasized to N1 alone (N1 and N2 and N3 ). Five cases (50%) of N1 carcinoids metastasized to N2 (N1 and N2 and N3 ). Two cases (20%) of N1 carcinoids metastasized to N3 (N1 and N2 and N3 ). Single metastasis of N2 or N3 was 0 and 1, respectively (Fig 1C). Lymph Node Metastasis and Invasion to Neighboring Organs Sixteen (5.6%) of 284 thymomas with invasion to neighboring organs were N. On the other hand, only 3 (0.003%) of 771 thymomas without invasion to neighboring organs were N. Forty-four (28.8%) of 153 thymic carcinomas with invasion to neighboring organs were N. Only 4 (14.8%) of 27 thymic carcinomas without invasion to neighboring organs were N. Nine (37.5%) of 24 thymic carcinoids with invasion of the neighboring organs were N, whereas only 2 (12.5%) of 16 thymic carcinoids without invasion of the neighboring organs were N.
3 Ann Thorac Surg KONDO AND MONDEN 2003;76: METASTASIS OF THYMIC EPITHELIAL TUMORS 1861 GENERAL THORACIC Fig 2. Survival curve of thymic epithelial tumors according to N factor. (A) Survival curve of thymoma according to N factor (thin straight line) thymoma with N0 (dark dotted line) thymoma with N1 (thick line) thymoma with N2. (B) Survival curve of thymic carcinoma according to N factor (thin straight line) carcinoma with N0 (dark dotted line) carcinoma with N1 (thick line) carcinoma with N2 (light dotted line) carcinoma with N3. Fig 1. Lymph node metastasis of thymic epithelial tumors The number in each circle is the number of the case. (LN lymph node.) (A) Pattern of lymph node metastasis of thymoma. (B) Pattern of lymph node metastasis of thymic carcinoma. (C) Pattern of lymph node metastasis of thymic carcinoid. Survival Curve of Thymic Epithelial Tumors According to N Factor Figure 2 shows the survival curves according to N factor of the thymoma and thymic carcinoma. The 5-year survival rates of N (n 895), N1 and N2 (n 13), and N2 (n 5) thymoma were 95.6%, 61.5%, and 20%, respectively (Fig 2A). There was a significant difference in survival rate between thymoma without lymph node metastasis and thymoma with lymph node metastasis (p ). Although the survival rate of patients with N2 thymoma was worse than that of patients with (N1 and N2 ) thymoma, no significant difference between them was observed. The 5-year survival rates of N (n 104), N1 and N2 and N3 (n 20), N2 and N3 (n 15), and N3 (n 11) thymic carcinoma were 56.0%, 42.1%, 29.3%, and 18.8%, respectively (Fig 2B). A significant difference in survival rate was observed between thymic carcinoma without lymph node metastasis (N ) and thymic carcinoma with lymph node metastasis (N ; p ). There was a significant difference of survival rate between patients with N carcinoma and N2 and N3 carcinoma (p ), and between N1 and N2 and N3 carcinoma and N3 carcinoma (p ). There was a tendency for survival rate of patients with thymic
4 GENERAL THORACIC 1862 KONDO AND MONDEN Ann Thorac Surg METASTASIS OF THYMIC EPITHELIAL TUMORS 2003;76: rate between M0 carcinoma and M1 carcinoma was observed. Multivariate Analysis of Survival in Thymoma and Thymic Carcinoma Survival of patients with thymoma was dependent on the clinical stage of Masaoka [3] (p 0.001) and complete resection (p 0.001; Table 2). Sex, age, histologic type, complications, lymph node metastasis, and distant metastasis were not factors predictive of survival. In thymic carcinoma, survival was dependent on lymph node metastasis (p 0.001) and complete resection (p 0.001). Sex, age histologic type, clinical stage of Masaoka [3], and distant metastasis were not factors predictive of survival. Fig 3. Survival curve of thymic epithelial tumors according to M factor. (A) Survival curve of thymoma according to M factor (straight line) thymoma without distant metastasis (dotted line) thymoma with distant metastasis. (B) Survival curve of thymic carcinoma according to M factor (straight line) carcinoma without distant metastasis (dotted line) carcinoma with distant metastasis. carcinoma to become worse according to progression of N factor. M Factor of Thymic Epithelial Tumors Only 13 (1.2%) of 1,073 thymomas had distant metastasis. Most of the metastatic sites in thymoma were lung (11 of 13, 84.6%). Twenty-two (12.0%) of 183 thymic carcinomas had distant metastasis. The metastatic sites in thymic carcinoma were lung (13 of 22, 59%), bone (5 of 22, 22.7%), and liver (5 of 22, 22.7%). Only 1 (2.5%) of 40 thymic carcinoids had distant metastasis. Figure 3 shows the survival curve according to M factor of the thymoma and thymic carcinoma. The 5-year survival rates of M0 (n 903) and M1 (n 10) thymoma were 95.0% and 57.1%, respectively. A significant difference in survival rate was observed between M0 thymoma and M1 thymoma (p ; Fig 3A). The 5-year survival rates of M0 (n 133) and M1 (n 16) thymic carcinoma were 51.3% and 34.7%, respectively (Fig 3B). No significant difference of survival Comment Several recent studies have reported prognostic factors for thymoma and thymic carcinoma using multivariate analysis [6, 10 20]. Clinical stage of Masaoka [10 12, 14 16], complete resection of the tumor [11, 13, 14], histologic classification (including that of Bernaz and associates [12, 14], one by Muller-Hermelink and coworkers [11, 15], and the World Health Organization classification [10]), Karnofsky performance status [12], and tumor size [14] are considered to be prognostic factors for thymoma. The current study also recognized clinical stage of Masaoka and complete resection of the tumor as prognostic factors of thymoma. In thymic carcinoma, clinical stage of Masaoka [17, 19], complete resection of the tumor [18, 19], histologic classification (squamous cell carcinoma versus other cancer) [6, 18, 19], Karnofsky performance status [18], and innominate vessel invasion [20] are considered to be prognostic factors. We recognized complete resection of the tumor as a prognostic factor for thymic carcinoma. Prognostic factors of multivariate analysis in the previous studies did not include N or M factors because of the rarity of thymoma with lymph node or distant metastasis and thymic carcinoma. The staging system of Masaoka [3] from 1981 is the most popular clinical staging system of thymoma. Our previous study demonstrated that this clinical staging system is an excellent system for predicting prognoses not only in thymoma but also in thymic carcinoma [8]. In the study, the 5-year survival rates of T1 N0 M0, T2 N0 M0, T3 N0 M0, and T4 N0 M0 thymoma were 100%, 98.3%, 89.2%, and 73.1%, respectively. A significant difference in survival rate was observed between T2 N0 M0 and T3 N0 M0 (p ) and between T3 N0 M0 and T4 N0 M0 (p ) [8]. Moreover, multivariate analysis in the current study demonstrated that survival of patients with thymoma was significantly dependent on the clinical stage of Masaoka (p 0.001). The 5-year survival rates of T1 plus T2 N0 M0, T3 N0 M0, and T4 N0 M0 thymic carcinomas were 88.2%, 54.5%, and 41.9%, respectively. A significant difference in survival rate was observed between the T1 plus T2 N0 M0 group and the T3 plus T4 N0 M0 (p 0.012) [8]. In patients with thymoma and thymic carcinoma without lymphogenous or hematogenous me-
5 Ann Thorac Surg KONDO AND MONDEN ;76: METASTASIS OF THYMIC EPITHELIAL TUMORS Table 2. Multivariate Analysis of Survival in Thymoma and Thymic Carcinoma Thymoma Thymic Carcinoma Feature Hazard Ratio p Value 95% CI Hazard Ratio p Value 95% CI GENERAL THORACIC Sex Age Histologic type a Complications b Stage c Lymph node metastasis Distant metastasis Complete resection a Spindle type versus others (thymoma), squamous cell carcinoma versus others (thymic carcinoma). hypergammaglobulinemia or hypogammaglobulinemia. c Stage I and II versus III and IV. CI confidence interval. b Myasthenia gravis, pure red cell aplasia, tastasis, the T factor was a valuable item that can predict the prognosis. Thymic carcinoma and carcinoid frequently show lymphogenous metastasis but thymoma does not. Lymphogenous metastasis was observed in 0% to 12% (mean, 2.6%) of patients with thymoma [9]. Sixteen percent to 35% of patients with thymic carcinoma and approximately 30% of patients with thymic carcinoid show lymphogenous or distant metastasis [6, 21, 22]. The current study demonstrated that the rates of lymphogenous metastasis in thymoma, thymic carcinoma, and thymic carcinoid were 1.8%, 26.8%, and 27.5%, respectively. Yamakawa and associates [9] in 1991 defined the status of lymphogenous metastasis as follows: metastasis to anterior mediastinal lymph nodes around the thymus as N1, metastasis to intrathoracic lymph nodes other than anterior mediastinal lymph nodes as N2, and metastasis to extrathoracic lymph nodes as N3. They regarded N1 as the primary lymph nodes of thymoma. We examined the pattern of lymphogenous metastasis in thymic epithelial tumor according to this N factor classification. Most tumors with lymph node metastasis metastasized to N1 (thymoma; 90%, thymic carcinoma; 69%, thymic carcinoid; 91%). Eighteen percent, 44%, and 60% of N1 tumors in thymoma, thymic carcinoma, and thymic carcinoid, respectively, metastasized to N2 or N3. Thymoma (11%) and thymic carcinoid (9%) infrequently had a skip metastasis to N2 or N3, whereas one third of thymic carcinomas had skip metastasis to N2 or N3. From these data we think that it is reasonable to consider N1 to be the primary lymph node in thymoma and thymic carcinoid. However, because thymic carcinoma easily undergoes skip metastasis, it may be not proper to consider N1 to be a primary lymph node in thymic carcinoma. Thymic epithelial tumor with invasion to neighboring organs easily metastasizes to lymph nodes compared with tumors without invasion (thymoma, 5.6% versus 0.003%; thymic carcinoma, 28.8% versus 14.8%; thymic carcinoid, 37.5% versus 12.5%). We conclude that it is necessary to dissect or sample lymph nodes of N1 in thymic carcinoma and thymic carcinoid, as well as in thymoma with invasion to neighboring organs. A significant difference in survival rate was observed between N and N in thymoma and thymic carcinoma. Multivariate analysis demonstrated that survival was dependent on lymph node metastasis in patients with thymoma (p 0.053) and thymic carcinoma (p 0.001). Moreover, the prognosis tends to become worse according to the progression of N factor. The N factor in thymic epithelial tumor was also one of the indicators predictive of survival, although it weakly influenced the survival in patients with thymoma compared with those with thymic carcinoma. The current study demonstrated the rate of hematogenous metastasis in thymoma. Hematogenous metastasis was observed in 0% to 10% (mean, 5.5%) of patients with thymoma [9]. Frequent metastatic sites for thymic epithelial tumor were the lung (thymoma, 84.6%; thymic carcinoma, 59%), followed by bone and liver. Although M1 thymoma and M1 thymic carcinoma showed worse prognoses compared with M0 thymoma and M0 thymic carcinoma, multivariate analysis demonstrated that survival of patients with thymoma (p 0.743) or thymic carcinoma (p 0.819) is not dependent on distant metastasis. In patients with thymic epithelial tumor, the M factor influences the survival less than T and N factors. In general, M factor strongly influences the survival in most cancers. This complicated relationship between N factor and M factor may be the reason why no TNM classification of thymic epithelial tumor has been established yet. In conclusion, T factor (invasiveness) was an excellent factor that can predict prognosis in not only thymoma but also thymic carcinoma. N factor (lymph node metastasis) is also one of the predictors of survival, although thymoma infrequently metastasizes to the lymph node. It is reasonable to consider the anterior mediastinal lymph node group (N1) to be a primary lymph node of thymic epithelial tumor because of its frequency and pattern of metastasis, anatomic location, and prognosis, although in thymic carcinoma skip metastasis occurs easily. The M
6 GENERAL THORACIC 1864 KONDO AND MONDEN Ann Thorac Surg METASTASIS OF THYMIC EPITHELIAL TUMORS 2003;76: factor (distant metastasis) influences the survival less than T and N factors. References 1. Bergh NP, Gatzinsky P, Larsson S, Lundin P, Ridell B. Tumors of the thymus and thymic region: I. Clinicopathological studies on thymomas. Ann Thorac Surg 1978;25: Wilkins EW Jr, Castleman B. Thymoma: a continuing survey at the Massachusetts General Hospital. Ann Thorac Surg 1979;28: Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48: Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol 1999;111: Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, eds. Atlas of tumor pathology. Third series, Fascicle 21. Washington, D.C.: Armed Forces Institute of Pathology, Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991;67: Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. Am J Clin Pathol 2000;114: Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76: Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative tumor-node-metastasis classification of thymoma. Cancer 1991;68: Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94: Lardinois D, Rechsteiner R, Lang RH, et al. Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 2000;69: Gripp S, Hilgers K, Wurm R, Schmitt G. Thymoma: prognostic factors and treatment outcomes. Cancer 1998;83: Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996;112: Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60: Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994;74: Pescarmona E, Rendina EA, Venuta F, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 1990;50: Hsu HC, Huang EY, Wang CJ, Sun LM, Chen HC. Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2002;52: Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94: Liu HC, Hsu WH, Chen YJ, et al. Primary thymic carcinoma. Ann Thorac Surg 2002;73: Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115: Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma. Ten years experience in twenty patients. J Thorac Cardiovasc Surg 1994;107: Economopoulos GC, Lewis JW Jr, Lee MW, Silverman NA. Carcinoid tumors of the thymus. Ann Thorac Surg 1990;50: INVITED COMMENTARY Doctors Kondo and Monden have organized a large contemporary database to see if the TNM staging system would fit thymic epithelial tumors. After a careful review of their data I believe the answer to be no for thymoma and maybe for thymic carcinoma. A staging system is valuable to estimate prognosis, decide on therapy and to compare results. Most would agree that simplicity and clinical validity are the two cardinal features of a successful staging system. Unnecessary subdivisions of tumor characteristics result in survival curves that do not separate well (and hence reduce the statistical difference between groups of patients) and make the system needlessly complex and difficult to remember. Clinical validity relates to the most important tumor variables (proven prognostic factors derived from large high quality databases utilizing multivariate analysis) for that specific tumor. For example, in soft tissue sarcoma, the histologic grade of the tumor is by far the most important prognostic variable while the lymph node status is not really relevant. The art of designing and comparing tumor staging schemes is complex and not standardized. A recent paper examining this problem in detail using thymoma as a model is worth reviewing to understand the uncertainties even our biostatistician colleagues have in this very complex area [1]. Less than 2% of patients with thymomas have nodal metastases. Only 1% of patients with thymoma have distant metastases. The rarity of this biologic behavior indicates that the N factor would not be a good candidate for stratifying survival in a staging system. This is emphasized by the p value in the multivariate analysis indicating a modification of the Masaoka system (stage 1, 2 vs 3, 4) was far superior (p 0.001) to nodal metastases (p 0.053) for predicting survival. While the Masaoka staging system is widely used, most agree it could be improved upon as there is no difference between stage 1 and 2 in almost all modern reports, stage 3 is heterogeneous and the new WHO histologic grading system is not used (most reports indicate the histologic type of thymoma stratifies survival, as well as the Masaoka stage, and is independently predictive of survival). I do not think the TNM system would be appropriate for thymoma given the information in this report. In thymic carcinoma lymph node metastases are relatively common (27% of cases) and there is a difference in survival between node negative and positive patients by The Society of Thoracic Surgeons /03/$30.00 Published by Elsevier Inc doi: /s (03)01316-x
Clinical Usefulness of the WHO Histological Classification of Thymoma
Original Article Clinical Usefulness of the WHO Histological Classification of Thymoma Satoshi Sonobe, MD, 1 Hideaki Miyamoto, MD, 1 Hiroshi Izumi, MD, 2 Bunsei Nobukawa, MD, 2 Toshiro Futagawa, MD, 1
More informationThymic epithelial tumors mainly consist of thymoma,
Therapy for Thymic Epithelial Tumors: A Clinical Study of 1,320 Patients From Japan Kazuya Kondo, MD, PhD, and Yasumasa Monden, MD, PhD Department of Oncological and Regenerative Surgery, School of Medicine,
More informationWHO Histologic Classification is a Prognostic Indicator in Thymoma
WHO Histologic Classification is a Prognostic Indicator in Thymoma Kazuya Kondo, MD, PhD, Kiyoshi Yoshizawa, MD, PhD, Masaru Tsuyuguchi, MD, PhD, Suguru Kimura, MD, PhD, Masayuki Sumitomo, MD, Junji Morita,
More informationIn the 1960s, thymomas were classified into two categories: Staging System of Thymoma MALIGNANCIES OF THE THYMUS. Akira Masaoka, MD, PhD S304
MALIGNANCIES OF THE THYMUS Akira Masaoka, MD, PhD Introduction: Thirty years have gone by since the Masaoka staging system of thymoma was proposed in 1981. Although the Masaoka staging system has been
More informationThe Role of Radiotherapy for Thymic Carcinoma
The Role of Radiotherapy for Thymic Carcinoma Tetsuo Nonaka 1,2, Yoshio Tamaki 1, Keiko Higuchi 1, Hiroyuki Katoh 1, Masumi Nakahashi 1, Hiroyuki Horikoshi 1, Kenro Takahashi 3, Koichi Minato 4, Shiro
More informationThymic neoplasms are the most common tumors of
Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and
More informationThymic carcinoma has been recognized as an entity that is different. Treatment and Prognosis of Thymic Carcinoma. A Retrospective Analysis of 40 Cases
3115 Treatment and Prognosis of Thymic Carcinoma A Retrospective Analysis of 40 Cases Kazuhiko Ogawa, M.D. 1 Takafumi Toita, M.D. 1 Takashi Uno, M.D. 2 Nobukazu Fuwa, M.D. 3 Yasumasa Kakinohana, Ph.D.
More informationThymic malignancies have often been poorly understood,
MALIGNANCIES OF THE THYMUS Evaluation and Treatment of Stage I and II Thymoma Frank C. Detterbeck, MD Abstract: Thymomas are relatively uncommon. Nevertheless, an accumulation of studies (mostly retrospective,
More informationThymoma and Thymic Carcinoma
Thymoma and Thymic Carcinoma Protocol applies to thymic epithelial tumors located in any area of the mediastinum. Procedures Biopsy Resection Protocol revision date: January 2004 No AJCC/UICC staging system
More informationPrognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems
Original Article Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems Geun Dong Lee 1, Hyeong Ryul Kim 2, Se Hoon Choi 2, Yong-Hee Kim 2,
More informationPostoperative Radiotherapy for Completely Resected Stage II or III Thymoma
ORIGINAL ARTICLE Postoperative Radiotherapy for Completely Resected Stage II or III Thymoma Ji Hyun Chang, MD,* Hak Jae Kim, MD, PhD,* Hong-Gyun Wu, MD, PhD,* Joo Hyun Kim, MD, PhD, and Young Tae Kim,
More informationThymic epithelial tumors (TETs) are rare neoplasms arising
ORIGINAL ARTICLE Thymoma A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD,* Alexander Marx, MD, Philipp Ströbel, MD, Edwin Bölke, MD,*
More informationSurgical and oncological outcomes of thoracoscopic thymectomy for thymoma
Review Article on Thoracic Surgery Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma Makoto Odaka, You Tsukamoto, Takamasa Shibasaki, Shohei Mori, Hisatoshi Asano, Makoto Yamashita,
More informationD pects of the pathophysiology and treatment of thymomas
CURRENT REVIEW Thymoma: Results of 241 Operated Cases Giuliano Maggi, MD, Caterina Casadio, MD, Antonio Cavallo, MD, Roberto Cianci, MD, Massimo Molinatti, MD, and Enrico Ruffini, MD Department of Thoracic
More informationDesign: Retrospective, clinicopathologic analysis of our experience and a review of recent literature.
Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors : a clinicopathologic study of 108 patients and literature review CHEST, March,
More informationSurgical treatment of thymoma: an 11-year experience with 761 patients
European Journal of Cardio-Thoracic Surgery 49 (2016) 1144 1149 doi:10.1093/ejcts/ezv288 Advance Access publication 30 August 2015 ORIGINAL ARTICLE Cite this article as: Zhao Y, Shi J, Fan L, Hu D, Yang
More informationOutcome of nonsurgical treatment for locally advanced thymic tumors
Original Article Outcome of nonsurgical treatment for locally advanced thymic tumors Chang-Lu Wang 1, Lan-Ting Gao 1, Chang-Xing Lv 1, Lei Zhu 2, Wen-Tao Fang 3 1 Department of Radiation Oncology, 2 Department
More informationInvasive Thymoma: The Role of Mediastinal Irradiation Following Complete or Incomplete Surgical Resection
Invasive Thymoma: The Role of Mediastinal Irradiation Following Complete or Incomplete Surgical Resection By Walter J. Curran, Jr, Michael J. Kornstein, John J. Brooks, and Andrew T. Turrisi III To evaluate
More informationProtocol for the Examination of Specimens From Patients With Thymic Tumors
Protocol for the Examination of Specimens From Patients With Thymic Tumors Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual For accreditation
More informationStandardized definitions and policies of minimally invasive thymoma resection
Perspective Standardized definitions and policies of minimally invasive thymoma resection Alper Toker 1,2 1 Department of Thoracic Surgery, Istanbul Medical School, Istanbul University, Istanbul, Turkey;
More informationProtocol for the Examination of Specimens From Patients With Thymoma and Thymic Carcinoma
Protocol for the Examination of Specimens From Patients With Thymoma and Thymic Carcinoma Protocol applies to thymic epithelial tumors located in any area of the mediastinum. No AJCC/UICC TNM Staging System
More informationPathology of Mediastinal Tumors
SAMO Meeting Lucerne 2009 Pathology of Mediastinal Tumors Alex Soltermann Most common lesions (adults) Clinical presentation 50% of the patients are asymptomatic, lesion discovered incidentally Symptoms
More informationComparison of Stages I II Thymoma Treated by Complete Resection With or Without Adjuvant Radiation
ORIGINAL ARTICLES: Comparison of Stages I II Thymoma Treated by Complete Resection With or Without Adjuvant Radiation Sunil Singhal, MD, Joseph B. Shrager, MD, David I. Rosenthal, MD, Virginia A. LiVolsi,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationLong-Term Outcome After Multimodality Treatment for Stage III Thymic Tumors
Long-Term Outcome After Multimodality Treatment for Stage III Thymic Tumors Federico Venuta, MD, Erino A. Rendina, MD, Flavia Longo, MD, Tiziano De Giacomo, MD, Marco Anile, MD, Edoardo Mercadante, MD,
More informationTreatment and prognosis of type B2 thymoma
Song et al. World Journal of Surgical Oncology 2014, 12:291 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Treatment and prognosis of type B2 thymoma Zhengbo Song 1,2, Xiangyu Jin 1,2 and Yiping
More informationThymomas have long attracted interest for a number
Clinical Value of the WHO Classification System of Thymoma Frank C. Detterbeck, MD Division of Thoracic Surgery, Yale University, New Haven, Connecticut Since the World Health Organization (WHO) histologic
More informationThymomas are tumors of epithelial cell origin arising. Preoperative CT Findings of Thymoma are Correlated with Postoperative Masaoka Clinical Stage
Preoperative CT Findings of Thymoma are Correlated with Postoperative Masaoka Clinical Stage Yan-juan Qu, MS, Guo-bing Liu, MS, He-shui Shi, MS, PhD, Mei-yan Liao, MS, PhD, Gui-fang Yang, MS, PhD, Zhi-xiong
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationEvaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival
Ried et al. World Journal of Surgical Oncology (2017) 15:214 DOI 10.1186/s12957-017-1283-4 RESEARCH Open Access Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and
More informationThe role of adjuvant chemotherapy following resection of early stage thymoma
Perspective The role of adjuvant chemotherapy following resection of early stage thymoma Masatsugu Hamaji Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto,
More informationPrognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection
Prognostic Factors in Thymic Epithelial Tumors Undergoing Complete Resection Charalambos Zisis, MD, Dimitra Rontogianni, MD, Chara Tzavara, MD, Kalliopi Stefanaki, MD, Antonios Chatzimichalis, MD, Antonios
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationMyasthenia Gravis with Thymoma: Analysis of and Postoperative Prognosis for 65 Patients with Thymomatous Myasthenia Gravis
Myasthenia Gravis with Thymoma: Analysis of and Postoperative Prognosis for 65 Patients with Thymomatous Myasthenia Gravis Yasumasa Monden, M.D., Kazuya Nakahara, M.D., Katsumi Kagotani, M.D., Yoshitaka
More informationThymoma is defined as a tumor derived from epithelial
Thymic Neuroendocrine Carcinoma and Thymoma Are Both Associated With Increased Risk of Extrathymic Malignancy: A 20-Year Review of a Single Institution Yi-Ting Yen, MD, Wu-Wei Lai, MD, Ming-Ho Wu, MD,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationThymic epithelial tumors (TETs), including thymomas,
Evolution of Classification of Thymic Epithelial Tumors in the Era of Dr Thomas V. Colby Anja C. Roden, MD Context. Numerous histomorphologic and staging classifications of thymic epithelial tumors (TETs)
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationMaterials and methods. Introduction
Original Article Comparison of the Masaoka-Koga staging and the International Association for the Study of Lung Cancer/the International Thymic Malignancies Interest Group proposal for the TNM staging
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationUsing the World Health Organization Classification of Thymic Epithelial Neoplasms to Describe CT Findings
Using the World Health Organization Classification of Thymic Epithelial Neoplasms to Describe CT Findings Noriyuki Tomiyama 1 Takeshi Johkoh 2 Naoki Mihara 2 Osamu Honda 2 Takenori Kozuka 2 Mitsuhiro Koyama
More informationTHYMIC CARCINOMAS AN UPDATE
THYMIC CARCINOMAS AN UPDATE Mark R. Wick, M.D. University of Virginia Medical Center Charlottesville, VA CARCINOMA OF THE THYMUS General Clinical Features No apparent gender predilection Age range of 35-75
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationNeoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up
ORIGINAL ARTICLE Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up Marco Lucchi, MD,* Franca Melfi, MD,* Paolo Dini, MD,* Fulvio Basolo, MD,
More informationThymic Tumors. Feiran Lou MD. MS. Kings County Hospital Department of Surgery
Thymic Tumors Feiran Lou MD. MS. Kings County Hospital Department of Surgery Case HPI 53 yo man referred from OSH for anterior mediastinal mass. Initially presented with leg weakness and back pain for
More informationOn the Histologic Heterogeneity of Thymic Epithelial Neoplasms: Impact of Sampling in Subtyping and Classification of Thymomas
Stránka č. 1 z 8 cme.medscape.com To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/0683 On the Histologic Heterogeneity
More informationMost primary thymic epithelial neoplasms represent
Atypical Thymoma: A Report of Seven Patients Johanna L. Baran, BS, Cynthia M. Magro, MD, Mark A. King, MD, Thomas E. Williams, Jr, MD, PhD, and Patrick Ross, Jr, MD, PhD School of Medicine and Public Health,
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationOriginal Article Clinicopathological features of type AB thymoma with liver metastases
Int J Clin Exp Pathol 2014;7(12):8700-8705 www.ijcep.com /ISSN:1936-2625/IJCEP0002983 Original Article Clinicopathological features of type AB thymoma with liver metastases Zhenzheng Wang 1*, Hui Li 2*,
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationT with myasthenia gravis (MG) [l-31. Thymothymectomy
Recurrent Thymoma in Patients With Myasthenia Gravis Mikio Ohmi, MD, and Masahiro Ohuchi, MD Division of Thoracic and Cardiovascular Surgery, Sendai National Hospital, Sendai, Japan One hundred sixty-six
More informationMyasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5
Myasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5 Disclosures Outline History of Thymus Anatomy of Thymus Pathophysiology of Myasthenia Gravis Medical Management of Myasthenia Gravis Surgical
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationJournal of Cardiothoracic Surgery
Journal of Cardiothoracic Surgery BioMed Central Research article The role of a pseudocapsula in thymic epithelial tumors: outcome and correlation with established prognostic parameters. Results of a 20-year
More informationResection of Thymic Carcinoma in a Patient with Thoracic Aortic Aneurysm
Case Report Resection of Thymic Carcinoma in a Patient with Thoracic Aortic Aneurysm Makoto Nonaka, MD, 1 Mitsutaka Kadokura, MD, 1 Shigeru Yamamoto, MD, 1 Daisuke Kataoka, MD, 1 Atsushi Bito, MD, 1 Mitsuru
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationARRO Case Thymoma. Jordan Kharofa, MD Elizabeth Gore, MD Medical College of Wisconsin
ARRO Case Thymoma Jordan Kharofa, MD Elizabeth Gore, MD Medical College of Wisconsin History HPI 54 yo male who presented to PCP with complaining subacute shortness of breath and chest pain. Pain increased
More informationValidation of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients
Validation of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic Surgery Shanghai Chest Hospital AATS,Seattle, April
More informationThymoma: a review of the clinical and pathological findings in 65 cases
Original Article Article original Thymoma: a review of the clinical and pathological findings in 65 cases Brita Sperling;* Jeff Marschall, MD; Renee Kennedy, MD; Punam Pahwa, PhD; Rajni Chibbar, MD* Introduction:
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationTHYMOMAS AND THYMIC CARCINOMAS: A REVIEW ON PATHOLOGY, PRESENTATION, STAGING, TREATMENT, AND NOVEL SYSTEMIC THERAPIES
THYMOMAS AND THYMIC CARCINOMAS: A REVIEW ON PATHOLOGY, PRESENTATION, STAGING, TREATMENT, AND NOVEL SYSTEMIC THERAPIES Keisuke Miyamoto, 1 *Jared D. Acoba 1,2 1. Internal Medicine Department, University
More informationThymic malignancies are relatively uncommon, with an. Standard Outcome Measures for Thymic Malignancies ITMIG DEFINITIONS AND POLICIES
ITMIG DEFINITIONS AND POLICIES Standard Outcome Measures for Thymic Malignancies James Huang, MD, Frank C. Detterbeck, MD,* Zuoheng Wang, PhD,* and Patrick J. Loehrer, Sr, MD This previously published
More informationIterative Surgical Treatment for Repeated Recurrences After Complete Resection of Thymic Tumors
GENERAL THORACIC Iterative Surgical Treatment for Repeated Recurrences After Complete Resection of Thymic Tumors Alfonso Fiorelli, MD, PhD, Antonio D Andrilli, MD, PhD, Camilla Vanni, MD, Roberto Cascone,
More informationOriginal Article Thymic epithelial tumors: a clinicopathologic study of 249 cases from a single institution
Int J Clin Exp Pathol 2014;7(11):7760-7767 www.ijcep.com /ISSN:1936-2625/IJCEP0002645 Original Article Thymic epithelial tumors: a clinicopathologic study of 249 cases from a single institution Xue-Ying
More informationThe major prognostic factors of thymomas: about a Tunisian study of 100 cases
pathologica 2015;107:9-13 Original article The major prognostic factors of thymomas: about a Tunisian study of 100 cases M. Mlika 1, M.S. Boudaya 2, S. Laabidi 3, Y. Zaimi 2, H. Smadhi 2, A. Marghli 2,
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationMasaoka Staging is of Prognostic Relevance in Type B3 / C Thymomas
Masaoka Staging is of Prognostic Relevance in Type B3 / C Thymomas T. LUEBKE 1, K.T.E. BECKURTS 1, C. WICKENHAUSER 2, P. SCHNEIDER 1, A. H. HOELSCHER 1 and S.P. MOENIG 1 1 Department of Visceral and Vascular
More informationRegion: 11. Clinic6patholo cal Studies
Tumors of the Thvmus and ThVIIliC Region: 11. Clinic6patholo cal Studies on Hodgkin s Disease of Re Thymus N. P. Bergh, M.D., P. Gatzinsky, M.D., S. Larsson, M.D., P. Lundin, M.D., and B. Ridell, M.D.
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationClinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports
Original Article Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports Mitsuro Fukuhara, Mitsunori Higuchi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe,
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationCase Presentation HPI. PMHx: HTN, BPH, psychiatric disorder, negative cardiac stress test 4/2010. Allergies: NKDA
Case Presentation HPI 62 year-old male presents with several episodes of anterior chest pain. Full cardiac evaluation was negative for ischemia. CT scan revealed a 4cm anterior mediastinal mass. Pt denies
More informationPrinciples and Practice of Radiation Oncology. 4 th edition. Chapter 45. Mediastinum and Trachea
Principles and Practice of Radiation Oncology 4 th edition Chapter 45 Mediastinum and Trachea Tony Y. Eng 1, Todd J. Scarbrough 2, Charles R. Thomas, Jr. 3 1 Associate Professor 3 Associate Professor and
More informationPrognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer
Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationAlthough thymic tumors are the most common tumors of
ORIGINAL ARTICLE The Role of Radiation Therapy in Malignant Thymoma A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA,* Eric T. Shinohara, MD,* Mengye Guo, PhD,
More informationBecause of the indolent course and sporadic occurrence
Thymic Tumors Frank C. Detterbeck, MD, and Alden M. Parsons, MD Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Thymic tumors include thymic carcinoma, which
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationPleomorphic carcinoma of the lung: which CT findings predict poor prognosis?
Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Poster No.: C-1887 Congress: ECR 2015 Type: Scientific Exhibit Authors: A. Fujisaki, T. Aoki, S. Kinoshita, Y. Hayashida, Y.
More informationThe Role of Adjuvant Radiation Therapy for Resected Stage III Thymoma: A Population-Based Study
GENERAL THORACIC The Role of Adjuvant Radiation Therapy for Resected Stage III Thymoma: A Population-Based Study Benny Weksler, MD, Manisha Shende, MD, Katie S. Nason, MD, MPH, Angela Gallagher, CRNP,
More informationIn the mid 1970s, visceral pleural invasion (VPI) was included
ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More information